As biopharmaceutical company, we aim to accelerate the development of highly innovative programs with strong therapeutical potential.
ABAXYS represents a new paradigm for Drug Discovery in Neuroscienses.
Our Mission & Vision
Build-up a ‘First-/Best -in-Class’ Innovative Portfolio in Human Neurodegenerative Diseases.
ABAXYS Therapeuthics aims to become a key player and first-choice partner in the area of human CNS diseases. We want to contribute to the development of highly innovative therapeutic solutions for neurodegenerative diseases.
Our approach will significantly reduce the time-to-clinics of efficacious disease modifying therapies for neurodegenerative diseases.
Our Key Approach
Our strategy is based on a business model which uses the local and European top R&D ecosystem to deliver disruptive Preclinical packages contributing to High Value Pharma Therapeutic programs
1
Hit Identification
With our Data Mining approach, we are able to efficiently identify new Hits.
2
Lead Optimization
With our Big Data and Simulation approach, we are able to accelerate the Preclinical process (from 3-5 years in only 6 months) by replacing lab, in-vitro, in-vivo experience with in-sillico validation.
3
Animal Modeling
With our Bio-imaging approach, we do not have to kill the Animal Model to see the impact of a drug. Thus we are able to follow the evolution of the disease, see the impact of a molecule and better predict the efficacy in human.
Our Board
A team profile essential for company needs, combining a long experience and robust know-how in neurosciences discovery, R&D, company creation and financing.
Our Team
-
-
-
-
Yolande HussCo-founder & Board Member
-
-
-
-
Yolande has long experience in molecular and cell research in neurosciences, particularly in the fields of biomarkers, neurostem cells and selective KO mice generation. She has a successful career path in academic research at IGBMC and at Center of Neurochemistry (France). She shares a passion for therapeutic discovery.
Our Partners





